Phosphodiesterase inhibitors vs placebo
Adverse events · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted3 studies · 138 participantsGRADE not reported
Findings
What do systematic reviews say?
9 questions · 10 findings · 4 reviews
No studies found 2 · 20%GRADE not reported 1 · 10%Very low 2 · 20%Low 3 · 30%Moderate 2 · 20%High 0 · 0%
Phosphodiesterase 5 inhibitors (PDE5i) vs placebo
Serious adverse events · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
- Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedModerate
Phosphodiesterase 5 inhibitors (PDE5i) vs placebo
Withdrawals due to adverse events · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
- Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedModerate
Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors
Minor adverse events · erectile dysfunction in men with obstructive sleep apnoea
It is very uncertain whether continuous positive airway pressure (CPAP) changes minor adverse events compared with phosphodiesterase type 5 inhibitors (very low certainty).
1 finding from 1 review
- Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes onlyRR 1.33 [0.34, 5.21]1 study · 40 participantsVery low
Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors
Serious adverse events · erectile dysfunction in men with obstructive sleep apnoea
1 finding from 1 review
- Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 40 participantsVery low
PDEI plus alpha‐blocker vs PDEI alone
Adverse events
The review found no eligible studies for this question.
1 finding from 1 review
- Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
PDEI + 5‐ARI vs 5‐ARI alone
Adverse events
The review found no eligible studies for this question.
2 findings from 1 review
- Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
- Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes onlyRR 1.07 [0.84, 1.36]1 study · 695 participantsLow
PDEI vs placebo
Adverse events
PDEI may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
- Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes onlyRR 1.42 [1.21, 1.67]11 studies · 4386 participantsLow
PDEI vs alpha‐blocker
Adverse events
PDEI showed no clear difference in adverse events compared with alpha‐blockers (low certainty).
1 finding from 1 review
- Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes onlyRR 1.35 [0.8, 2.3]4 studies · 786 participantsLow